scispace - formally typeset
S

Shinae Kizaka-Kondoh

Researcher at Tokyo Institute of Technology

Publications -  110
Citations -  4936

Shinae Kizaka-Kondoh is an academic researcher from Tokyo Institute of Technology. The author has contributed to research in topics: Tumor hypoxia & Gene. The author has an hindex of 36, co-authored 102 publications receiving 4399 citations. Previous affiliations of Shinae Kizaka-Kondoh include Kyoto University.

Papers
More filters
Journal ArticleDOI

Role of TGF-β in EGF-induced transformation of NRK cells is sustaining high-level EGF-signaling1

TL;DR: The findings suggest that the major role of TGF‐β in this transformation system should be to counteract the ligand‐dependent down‐regulation of EGFR, thereby sustaining high‐level EGF‐signaling.
Journal ArticleDOI

Novel adherent CD11b+ Gr-1+ tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment.

TL;DR: It is suggested that MLACs may function as an initiator of the immunosuppressive tumor microenvironment and highlight a new therapeutic target to prevent the onset or delay malignant progression.
Journal ArticleDOI

Strategic design to create HER2-targeting proteins with target-binding peptides immobilized on a fibronectin type III domain scaffold

TL;DR: HBP-FLAP containing the YCAHNM peptide showed increased proteolysis-resistance, binding to HER2 with a dissociation constant (KD) of 58 nM in ELISA and 287NM in biolayer interferometry and specifically detects HER2-expressing cancer cells.
Journal ArticleDOI

Slicing Spheroids in Microfluidic Devices for Morphological and Immunohistochemical Analysis

TL;DR: A microfluidic device created from embedding resin for sectioning spheroids and according to morphological and immunohistochemical analyses of the slices of the spheroid, specific protein distribution was observed.
Journal ArticleDOI

Microfluidic Device for Screening for Target Cell-Specific Binding Molecules by Using Adherent Cells

TL;DR: A microfluidic device for screening molecules such as aptamers, antibodies, proteins, etc. for target cell-specific binding molecules and showed that the device could reduce anti-integrin antibodies to the detection limit of fluorescent measurement and collect anti-HER2 antibodies from the target cells.